About

The CSF is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.

CSF programmes are free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.

Membership of the CSF is free to everyone. Register as a member and have unlimited free access to all of the materials contained within the site.

Take our survey now
ACR 2023 Webinar
Forum LIVE
Cytokine Signalling Forum
Discussing Rheumatology Podcasts
FREEMEMBERSHIP

Publications

Free summaries and slides for a selection of papers

View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual steering committee members.

Podcasts

Listen on the go!

Here you will find a range of CSF podcasts recorded by our steering committee.

Congress Updates

The latest coverage of the biggest congresses in rheumatology

Coverage of key data relating to the science of cytokine signalling and new and developing therapeutic options that target cytokine signalling pathways presented at key congresses and reviewed for your information.

Online Educational Content

Free interactive tutorials, videos and assessments

A range of distance learning programmes to meet the educational need of healthcare professionals in achondroplasia. Key topics of interest have been identified through consultation and guidance from our Editorial Committee.

Latest Updates

Latest ▼
All

ACR 2023 - CSF coverage highlights the most relevant data on RA, PsA, and axSpA. Including our Preview Brochures highlighting key posters and oral presentations ahead of the congress.

Baricitinib in Juvenile Idiopathic Arthritis: An International, Phase 3, Randomised, Double-blind, Placebo-controlled, Withdrawal, Efficacy, and Safety Trial

EULAR 2023 - CSF coverage highlights the most relevant data on RA, PsA, and axSpA. Including our Preview Brochures highlighting key posters and oral presentations ahead of the congress.

AxSpA Podcast: Safety and Efficacy of Tofacitinib and Bimekizumab

Steering Committee